153 related articles for article (PubMed ID: 33878160)
1. Anti-inflammatory chemoprevention attenuates the phenotype in a mouse model of esophageal adenocarcinoma.
Baumeister T; Ingermann J; Marcazzan S; Fang HY; Oellinger R; Rad R; Engleitner T; Kleigrewe K; Anand A; Strangmann J; Schmid RM; Wang TC; Quante M
Carcinogenesis; 2021 Aug; 42(8):1068-1078. PubMed ID: 33878160
[TBL] [Abstract][Full Text] [Related]
2. High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome.
Münch NS; Fang HY; Ingermann J; Maurer HC; Anand A; Kellner V; Sahm V; Wiethaler M; Baumeister T; Wein F; Einwächter H; Bolze F; Klingenspor M; Haller D; Kavanagh M; Lysaght J; Friedman R; Dannenberg AJ; Pollak M; Holt PR; Muthupalani S; Fox JG; Whary MT; Lee Y; Ren TY; Elliot R; Fitzgerald R; Steiger K; Schmid RM; Wang TC; Quante M
Gastroenterology; 2019 Aug; 157(2):492-506.e2. PubMed ID: 30998992
[TBL] [Abstract][Full Text] [Related]
3. Telomere shortening accelerates tumor initiation in the L2-IL1B mouse model of Barrett esophagus and emerges as a possible biomarker.
Sahm V; Maurer C; Baumeister T; Anand A; Strangmann J; Schmid RM; Wang TC; Quante M
Oncotarget; 2022; 13():347-359. PubMed ID: 35178191
[TBL] [Abstract][Full Text] [Related]
4. Chronic High-Fat Diet Induces Early Barrett's Esophagus in Mice through Lipidome Remodeling.
Molendijk J; Nguyen TM; Brown I; Mohamed A; Lim Y; Barclay J; Hodson MP; Hennessy TP; Krause L; Morrison M; Hill MM
Biomolecules; 2020 May; 10(5):. PubMed ID: 32429496
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of esophageal adenocarcinoma formation and approaches to chemopreventive intervention.
Richmond E; Umar A
Semin Oncol; 2016 Feb; 43(1):78-85. PubMed ID: 26970126
[TBL] [Abstract][Full Text] [Related]
6. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
Wang F; Lv ZS; Fu YK
Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
[TBL] [Abstract][Full Text] [Related]
7. IL-1β transgenic mouse model of inflammation driven esophageal and oral squamous cell carcinoma.
Muthupalani S; Annamalai D; Feng Y; Ganesan SM; Ge Z; Whary MT; Nakagawa H; Rustgi AK; Wang TC; Fox JG
Sci Rep; 2023 Aug; 13(1):12732. PubMed ID: 37543673
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
Bresalier RS
Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
[TBL] [Abstract][Full Text] [Related]
9. Medical decision analysis of chemoprevention against esophageal adenocarcinoma.
Sonnenberg A; Fennerty MB
Gastroenterology; 2003 Jun; 124(7):1758-66. PubMed ID: 12806608
[TBL] [Abstract][Full Text] [Related]
10. High-Fructose Diet Alters Intestinal Microbial Profile and Correlates with Early Tumorigenesis in a Mouse Model of Barrett's Esophagus.
Proaño-Vasco A; Baumeister T; Metwaly A; Reitmeier S; Kleigrewe K; Meng C; Gigl M; Engleitner T; Öllinger R; Rad R; Steiger K; Anand A; Strangmann J; Thimme R; Schmid RM; Wang TC; Quante M
Microorganisms; 2021 Nov; 9(12):. PubMed ID: 34946037
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
12. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ
Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456
[TBL] [Abstract][Full Text] [Related]
13. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
14. Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.
Chemnitzer O; Götzel K; Maurer L; Dietrich A; Eichfeld U; Lyros O; Jansen-Winkeln B; Hoffmeister A; Gockel I; Thieme R
Dig Dis Sci; 2017 Dec; 62(12):3391-3401. PubMed ID: 29086334
[TBL] [Abstract][Full Text] [Related]
15. Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model.
Chen X; Li N; Wang S; Hong J; Fang M; Yousselfson J; Yang P; Newman RA; Lubet RA; Yang CS
Carcinogenesis; 2002 Dec; 23(12):2095-102. PubMed ID: 12507933
[TBL] [Abstract][Full Text] [Related]
16. Elimination of NF-κB signaling in Vimentin+ stromal cells attenuates tumorigenesis in a mouse model of Barrett's Esophagus.
Anand A; Fang HY; Mohammad-Shahi D; Ingermann J; Baumeister T; Strangmann J; Schmid RM; Wang TC; Quante M
Carcinogenesis; 2021 Apr; 42(3):405-413. PubMed ID: 33068426
[TBL] [Abstract][Full Text] [Related]
17. Esophageal Adenocarcinoma: Screening, Surveillance, and Management.
Mansour NM; Groth SS; Anandasabapathy S
Annu Rev Med; 2017 Jan; 68():213-227. PubMed ID: 27618753
[TBL] [Abstract][Full Text] [Related]
18. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
19. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of esophageal adenocarcinoma.
Abrams JA
Therap Adv Gastroenterol; 2008 Jul; 1(1):7-18. PubMed ID: 21180511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
